Purple Biotech (PPBT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Purple Biotech stock (PPBT) is currently trading at $3.96. Purple Biotech PS ratio (Price-to-Sales) is 58.08. Analyst consensus price target for PPBT is $34.00. WallStSmart rates PPBT as Sell.
- PPBT PE ratio analysis and historical PE chart
- PPBT PS ratio (Price-to-Sales) history and trend
- PPBT intrinsic value — DCF, Graham Number, EPV models
- PPBT stock price prediction 2025 2026 2027 2028 2029 2030
- PPBT fair value vs current price
- PPBT insider transactions and insider buying
- Is PPBT undervalued or overvalued?
- Purple Biotech financial analysis — revenue, earnings, cash flow
- PPBT Piotroski F-Score and Altman Z-Score
- PPBT analyst price target and Smart Rating
Purple Biotech
📊 No data available
Try selecting a different time range
Smart Analysis
Purple Biotech (PPBT) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Purple Biotech (PPBT) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Purple Biotech (PPBT) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 58.1x annual revenue
Very low institutional interest at 3.82%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Purple Biotech (PPBT) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.37) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (58.08) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -8.56%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -8.56% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PPBT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PPBT's Price-to-Sales ratio of 58.08x sits near its historical average of 56.55x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 77% below its historical high of 249.97x set in Sep 2024, and 1945% above its historical low of 2.84x in Apr 2020. Over the past 12 months, the PS ratio has compressed from ~128.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Purple Biotech (PPBT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Purple Biotech operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 10M in cash.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Purple Biotech.
Bottom Line
Purple Biotech offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Purple Biotech(PPBT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. The company is headquartered in Rehovot, Israel.